Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared a post on X:
“Ovarian cancer treatment is entering a new era!
In 89% of primary tumors, at least one ADC target (FRα, HER2, CDH6, TROP2, B7-H4) showed high expression.
Post-chemotherapy expression remained largely stable, opening doors for more durable, personalized ADC strategies in HGSOC.
Multi-target expression in 55% → Potential for combination therapies.
Highlights the urgent need to translate biomarker profiling into real-world impact.”
More posts featuring Galip Can Uyar on OncoDaily.